USPH Stock Forecast & Price Target

US Physical Therapy's positive outlook is underscored by robust revenue growth, particularly within its fast-growing industrial injury prevention business, which has demonstrated strong momentum over recent quarters. The company anticipates an increase in adjusted EBITDA for FY/25 to a range of $93 million to $97 million, reflecting an approximate 8.6% growth compared to the previous year. Additionally, the forecasted results indicate improvements in key financial metrics, highlighting a potential 17.1% growth in one revenue category and a 10.0% increase in another when compared to the prior year.

US Physical Therapy Inc. may face challenges moving forward, as 2026 will be the first year since before the COVID pandemic without pricing headwinds in its Medicare business, which is a significant revenue source. Despite this relief in pricing, the reliance on managed care programs and Medicare/Medicaid for revenue poses risks due to potential policy changes and reimbursement rate pressures. Additionally, the company’s core operations in outpatient physical therapy, which are sensitive to market fluctuations and competitive dynamics, could hinder growth despite the eventual easing of pricing pressures.